ProGnosis Biotech
ProGnosis Biotech is a Greek biotechnology company developing next-generation immunoassays for mycotoxin diagnostics, primarily serving dairy producers, processors, and feed suppliers in the Balkans ahead of Serbia's December 2026 EU regulatory alignment.
- Company typePrivate
- Founded2011
- HeadquartersLárissa, Greece
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What ProGnosis Biotech does
ProGnosis Biotech is a Greek-headquartered, privately held biotechnology company founded in 2011, operating in Lárissa with a headcount of 51-100 employees. The company develops next-generation immunoassays for clinical and food-safety diagnostics, with its current disclosed focus on diagnostic solutions for mycotoxin detection and control across the dairy supply chain — specifically aflatoxin B1 and M1 contamination, where its offering is differentiated on accuracy and precision.
The company's revenue model is built around hardware sales of diagnostic products (testing kits and related analytical services), targeting dairy producers, processors, and feed suppliers as its primary vertical. Go-to-market is event-driven, with engagement through industry conferences aimed at dairy-chain stakeholders in Serbia and the broader Balkans region. The strategic emphasis is positioned around Serbia's forthcoming alignment with the stricter EU mycotoxin threshold of 0.05 μg/kg, effective 1 December 2026, which creates an immediate compliance-driven demand for faster diagnostics and feed-risk management.
Material data gaps limit further characterization: no patents, certifications, named customer accounts, management team, funding history, or revenue figures are disclosed in the available sources. The company's own website currently displays only a verification/loading page, and the only documented activity in the source set is a March 2026 industry conference in Serbia. Ownership, investor backing, and product roadmap beyond aflatoxin diagnostics are not characterized.
ProGnosis Biotech firmographics
Firmographics- Name
- ProGnosis Biotech
- Website
- https://prognosis-biotech.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- ProGnosis Biotech is a Greek biotechnology company developing next-generation immunoassays for mycotoxin diagnostics, primarily serving dairy producers, processors, and feed suppliers in the Balkans ahead of Serbia's December 2026 EU regulatory alignment.
- Ownership category
- akta.pro rank
ProGnosis Biotech industry classification
Industry- Product category
- Mycotoxin Diagnostic Testing
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Testing Laboratories (8734)
- akta.pro primary industry
- Mycotoxin Testing (Aflatoxins, Ochratoxin, DON, ZEN, Fumonisins) (AFALAFAC)
- akta.pro secondary industries
- Residue & Contaminant Testing (Pesticides, Vet Drugs, Mycotoxins, Heavy Metals) (AFALAAAF), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)
Keywords
Where ProGnosis Biotech is headquartered
LocationHeadquarters
- HQ city
- Lárissa
- HQ country
- Greece
- HQ region
- Europe
Markets served
ProGnosis Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Diagnostic Products and Services: ProGnosis Biotech provides diagnostic solutions for mycotoxin detection in the dairy supply chain, likely offering testing kits, analytical services, and advisory solutions for feed-risk management and compliance with EU mycotoxin thresholds.
Go-to-market motion1 record
Marketing channels1 record
ProGnosis Biotech product offering
Product offeringCore offering
ProGnosis Biotech develops next-generation immunoassays for clinical diagnostics, specializing in mycotoxin detection and control across the dairy supply chain. The company provides diagnostic solutions for detecting and controlling aflatoxin B1 and M1 contamination, enabling dairy producers, processors, and feed suppliers to meet EU food safety regulations.
Product overview
Based on the available source data, ProGnosis Biotech appears to operate in the agricultural/food safety technology sector, specifically focused on mycotoxin detection and control solutions. The news source indicates they held a conference addressing aflatoxin B1 and M1 control across the dairy chain, highlighting expertise in dairy safety diagnostics. However, no specific named products, modules, or service offerings are detailed in the provided source material.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Serbia aligning with EU mycotoxin threshold of 0.05 μg/kg from 1 December 2026
Companies that use ProGnosis Biotech
Customer profileSegments1 record
Ideal customer profiles1 record
ProGnosis Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
ProGnosis Biotech partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights3 records
ProGnosis Biotech competitors and assessment
Company assessmentBroad incumbents
- Eurofins Scientific: Global leader in food and feed testing services with extensive mycotoxin analytical capabilities and reference laboratories. Competes with ProGnosis Biotech as a comprehensive food-safety services provider.
- SGS SA: Global inspection, verification, and testing company with a sizable food and agricultural testing division. Operates as a broad incumbent offering mycotoxin analysis among many other services.
- Bio-Rad Laboratories: Large diagnostics and life science company with immunoassay products and food safety testing reagents. Comparable in immunoassay technology base, though operating across much broader portfolios.
- PerkinElmer / Revvity: Global analytical instruments and diagnostics company with food safety testing reagents and instruments. Operates broadly in the same analytical technology space as ProGnosis Biotech.
Direct peers
- Gold Standard Diagnostics: European diagnostics company (formerly EuroProxima) producing ELISA kits for mycotoxins, veterinary drugs, and other contaminants. Closely comparable niche-specialist profile to ProGnosis Biotech.
- R-Biopharm: German diagnostics company specializing in ELISA and lateral flow test kits for mycotoxin detection in food and feed. Directly comparable to ProGnosis Biotech in core immunoassay technology and aflatoxin focus.
- Romer Labs: Austrian-based subsidiary of ERBER Group focused on mycotoxin testing kits and analytical services for the food and feed industry. Closely comparable product portfolio and customer base to ProGnosis Biotech.
- Neogen Corporation: US-based food safety diagnostics company offering a broad portfolio of test kits for mycotoxins, allergens, and pathogens. Comparable product category and target end-markets to ProGnosis Biotech.
- VICAM: Specialist in aflatoxin and mycotoxin testing solutions with a long-standing focus on immunoaffinity columns and rapid test kits. Directly comparable in aflatoxin diagnostic technology and target customers.
Emerging players
- Elabscience: China-based immunoassay kit manufacturer with a growing catalog of mycotoxin and food safety ELISA kits. Comparable as an emerging specialist targeting similar buyers in food safety.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
ProGnosis Biotech social profiles
Digital presenceProGnosis Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProGnosis Biotech leadership team
Management profileNumber of profiles
ProGnosis Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProGnosis Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProGnosis Biotech
What does ProGnosis Biotech do?
ProGnosis Biotech develops next-generation immunoassays for clinical diagnostics, specializing in mycotoxin detection and control across the dairy supply chain. The company provides diagnostic solutions for detecting and controlling aflatoxin B1 and M1 contamination, enabling dairy producers, processors, and feed suppliers to meet EU food safety regulations.
Is ProGnosis Biotech a public or private company?
ProGnosis Biotech is a private company. It is classified as unknown and is currently operating.
When was ProGnosis Biotech founded?
ProGnosis Biotech was founded in 2011. It employs 51 to 100 people.
Where is ProGnosis Biotech based?
ProGnosis Biotech is headquartered in Lárissa, Greece, in the Europe region.
How does ProGnosis Biotech make money?
One revenue line is on record: diagnostic Products and Services.
Who are ProGnosis Biotech's main competitors?
Broad incumbents on record are Eurofins Scientific, SGS SA, Bio-Rad Laboratories and PerkinElmer / Revvity. Direct peers are Gold Standard Diagnostics, R-Biopharm, Romer Labs, Neogen Corporation and VICAM. Elabscience is listed as an emerging player.
Does ProGnosis Biotech have an API?
No public API is recorded for ProGnosis Biotech.
What industry is ProGnosis Biotech in?
ProGnosis Biotech's product category is Mycotoxin Diagnostic Testing. Its primary akta.pro industry code is AFALAFAC, Mycotoxin Testing (Aflatoxins, Ochratoxin, DON, ZEN, Fumonisins), with a secondary code of AFALAAAF, Residue & Contaminant Testing (Pesticides, Vet Drugs, Mycotoxins, Heavy Metals). Its NAICS code is 325413 and its SIC code is 2835.